Tags

Type your tag names separated by a space and hit enter

Reduction in total plasma ghrelin levels following catecholamine depletion: relation to bulimic and depressive symptoms.
Psychoneuroendocrinology 2013; 38(9):1545-52P

Abstract

There is increasing preclinical and clinical evidence of the important role played by the gastric peptide hormone ghrelin in the pathogenesis of symptoms of depression and eating disorders. To investigate the role of ghrelin and its considered counterpart, peptide tyrosine tyrosine (PYY), in the development of bulimic and depressive symptoms induced by catecholamine depletion, we administered the tyrosine hydroxylase inhibitor alpha-methyl-paratyrosine (AMPT) in a randomized, double-blind, placebo-controlled crossover, single-site experimental trial to 29 healthy controls and 20 subjects with fully recovered bulimia nervosa (rBN). We found a decrease between preprandial and postprandial plasma ghrelin levels (p<0.0001) and a postprandial rise in plasma PYY levels (p<0.0001) in both conditions in the entire study population. Plasma ghrelin levels decreased in the entire study population after treatment with AMPT compared to placebo (p<0.006). AMPT-induced changes in plasma ghrelin levels were negatively correlated with AMPT-induced depressive symptoms (p<0.004). Plasma ghrelin and plasma PYY levels were also negatively correlated (p<0.05). We did not observe a difference in ghrelin or PYY response to catecholamine depletion between rBN subjects and healthy controls, and there was no correlation between plasma ghrelin and PYY levels and bulimic symptoms induced by catecholamine depletion. These findings suggest a relationship between catecholamines and ghrelin with depressive symptoms.

Authors+Show Affiliations

Department of Endocrinology, Diabetology & Clinical Nutrition, Inselspital, University of Bern, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23333252

Citation

Homan, Philipp, et al. "Reduction in Total Plasma Ghrelin Levels Following Catecholamine Depletion: Relation to Bulimic and Depressive Symptoms." Psychoneuroendocrinology, vol. 38, no. 9, 2013, pp. 1545-52.
Homan P, Grob S, Milos G, et al. Reduction in total plasma ghrelin levels following catecholamine depletion: relation to bulimic and depressive symptoms. Psychoneuroendocrinology. 2013;38(9):1545-52.
Homan, P., Grob, S., Milos, G., Schnyder, U., & Hasler, G. (2013). Reduction in total plasma ghrelin levels following catecholamine depletion: relation to bulimic and depressive symptoms. Psychoneuroendocrinology, 38(9), pp. 1545-52. doi:10.1016/j.psyneuen.2012.12.024.
Homan P, et al. Reduction in Total Plasma Ghrelin Levels Following Catecholamine Depletion: Relation to Bulimic and Depressive Symptoms. Psychoneuroendocrinology. 2013;38(9):1545-52. PubMed PMID: 23333252.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduction in total plasma ghrelin levels following catecholamine depletion: relation to bulimic and depressive symptoms. AU - Homan,Philipp, AU - Grob,Simona, AU - Milos,Gabriella, AU - Schnyder,Ulrich, AU - Hasler,Gregor, Y1 - 2013/01/16/ PY - 2012/10/29/received PY - 2012/12/13/revised PY - 2012/12/27/accepted PY - 2013/1/22/entrez PY - 2013/1/22/pubmed PY - 2014/5/16/medline KW - Bulimia nervosa KW - Catecholamines KW - Depression KW - Dopamine KW - Ghrelin KW - Norepinephrine KW - PYY remission SP - 1545 EP - 52 JF - Psychoneuroendocrinology JO - Psychoneuroendocrinology VL - 38 IS - 9 N2 - There is increasing preclinical and clinical evidence of the important role played by the gastric peptide hormone ghrelin in the pathogenesis of symptoms of depression and eating disorders. To investigate the role of ghrelin and its considered counterpart, peptide tyrosine tyrosine (PYY), in the development of bulimic and depressive symptoms induced by catecholamine depletion, we administered the tyrosine hydroxylase inhibitor alpha-methyl-paratyrosine (AMPT) in a randomized, double-blind, placebo-controlled crossover, single-site experimental trial to 29 healthy controls and 20 subjects with fully recovered bulimia nervosa (rBN). We found a decrease between preprandial and postprandial plasma ghrelin levels (p<0.0001) and a postprandial rise in plasma PYY levels (p<0.0001) in both conditions in the entire study population. Plasma ghrelin levels decreased in the entire study population after treatment with AMPT compared to placebo (p<0.006). AMPT-induced changes in plasma ghrelin levels were negatively correlated with AMPT-induced depressive symptoms (p<0.004). Plasma ghrelin and plasma PYY levels were also negatively correlated (p<0.05). We did not observe a difference in ghrelin or PYY response to catecholamine depletion between rBN subjects and healthy controls, and there was no correlation between plasma ghrelin and PYY levels and bulimic symptoms induced by catecholamine depletion. These findings suggest a relationship between catecholamines and ghrelin with depressive symptoms. SN - 1873-3360 UR - https://www.unboundmedicine.com/medline/citation/23333252/Reduction_in_total_plasma_ghrelin_levels_following_catecholamine_depletion:_relation_to_bulimic_and_depressive_symptoms_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0306-4530(13)00003-6 DB - PRIME DP - Unbound Medicine ER -